Sign Up Today and Learn More About Front Range Biosciences Stock

Invest in or calculate the value of your shares in Front Range Biosciences or other pre-IPO companies through EquityZen's platform.

Get Started

Front Range Biosciences Stock

Agricultural science for cannabis and hemp

About Front Range Biosciences Stock

Founded

2015

Headquarters

Boulder, CO, US

Total Funding

14.6M

CEO: Jon Vaught, PhD, Organic Chemistry, CU Boulder, 10 years biotech startup experience with 4 companies CSO: Chris Zalewski, PhD, Plant Biology, UC Davis, 20 years plant biotechnology experience COO: Nick Hofmeister, MBA, MIT, raised $250 million, co-founder 4 biotech companies Problem: Due to 60 years of prohibition, cannabis and hemp cultivators don’t have access to the bioscience tools that are used in modern agriculture. Cannabis and hemp growers are losing money due to disease, reduced yields, and un-differntiated product. Solution: Use known agricultural biotechnology (e.g., tissue culture, cryopreservation, analytical chemistry, genomics and marker assisted breeding) to improve yields, reduce disease, and create novel strains.

Front Range Biosciences Press Mentions

Stay in the know about the latest news on Front Range Biosciences

Front Range Biosciences Management

Leadership team at Front Range Biosciences

CEO, Founder

Jonathan Vaught

COO, Founder

Nick Hofmeister

Locked Features

Join now and verify your accreditation status to gain access to:

  • Front Range Biosciences current valuation
  • Front Range Biosciences stock price
  • Available deals in Front Range Biosciences and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Front Range Biosciences stock?

Accredited investors can buy pre-IPO stock in companies like Front Range Biosciences through EquityZen funds. These investments are made available by existing Front Range Biosciences shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Front Range Biosciences stock?

Shareholders can sell their Front Range Biosciences stock through EquityZen's private company marketplace. EquityZen's network includes over 300K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 41K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."